DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

15 Drugs in Development

15 Drugs in Development

DIGITAL CONTENT

13 NEWS #PharmaBuzz

media
13 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

15DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 1401436-95-0, Zandelisib [inn], Zandelisib [usan], Pwt143, Acc-524, Pwt-143

Molecular Formula

C₃₁H₃₈F₂N₈O

Molecular Weight

576.7 g/mol

InChI Key

WPFUFWIHMYZXSF-UHFFFAOYSA-N

FDA UNII

8Z28M5SX0X

Zandelisib is an orally bioavailable inhibitor of the delta isoform of phosphatidylinositide 3-kinase (PI3K), with potential antineoplastic activity. Upon oral administration, zandelisib selectively inhibits the delta isoform of PI3K and prevents the activation of the PI3K/AKT signaling pathway. This both decreases proliferation and induces cell death in PI3K-delta-overexpressing tumor cells. PI3K-delta plays a key role in the proliferation and survival of hematologic cancer cells. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells. PI3K, an enzyme often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.

1 2D Structure

Zandelisib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

4-[2-(difluoromethyl)benzimidazol-1-yl]-N-[2-methyl-1-[2-(1-methylpiperidin-4-yl)phenyl]propan-2-yl]-6-morpholin-4-yl-1,3,5-triazin-2-amine

2.1.2 InChI

InChI=1S/C31H38F2N8O/c1-31(2,20-22-8-4-5-9-23(22)21-12-14-39(3)15-13-21)38-28-35-29(40-16-18-42-19-17-40)37-30(36-28)41-25-11-7-6-10-24(25)34-27(41)26(32)33/h4-11,21,26H,12-20H2,1-3H3,(H,35,36,37,38)

2.1.3 InChI Key

WPFUFWIHMYZXSF-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC(C)(CC1=CC=CC=C1C2CCN(CC2)C)NC3=NC(=NC(=N3)N4CCOCC4)N5C6=CC=CC=C6N=C5C(F)F

2.2 Other Identifiers

2.2.1 UNII

8Z28M5SX0X

2.3 Synonyms

2.3.1 Depositor-Supplied Synonyms

1. 1401436-95-0

2. Zandelisib [inn]

3. Zandelisib [usan]

4. Pwt143

5. Acc-524

6. Pwt-143

7. Pw-143

8. 8z28m5sx0x

9. 4-[2-(difluoromethyl)benzimidazol-1-yl]-n-[2-methyl-1-[2-(1-methylpiperidin-4-yl)phenyl]propan-2-yl]-6-morpholin-4-yl-1,3,5-triazin-2-amine

10. 1,3,5-triazin-2-amine, 4-(2-(difluoromethyl)-1h-benzimidazol-1-yl)-n-(1,1-dimethyl-2-(2-(1-methyl-4-piperidinyl)phenyl)ethyl)-6-(4-morpholinyl)-

11. 1,3,5-triazin-2-amine, 4-[2-(difluoromethyl)-1h-benzimidazol-1-yl]-n-[1,1-dimethyl-2-[2-(1-methyl-4-piperidinyl)phenyl]ethyl]-6-(4-morpholinyl)-

12. 4-(2-(difluoromethyl)benzimidazol-1-yl)-n-(1,1-dimethyl-2-(2-(1-methyl-4-piperidyl)phenyl)ethyl)-6-morpholino-1,3,5-triazin-2-amine

13. Zandelisib [jan]

14. Unii-8z28m5sx0x

15. Zandelisib [who-dd]

16. Chembl4650214

17. Schembl12936730

18. Gtpl10627

19. Ex-a5471

20. Me-401; Pwt-143

21. Who 11202

22. Zinc148868634

23. At32468

24. Ac-35708

25. Example 51 [wo2012135160a1]

26. Hy-109198

27. Cs-0119144

28. A35 [wo2012135160a1]

2.4 Create Date

2012-11-19

3 Chemical and Physical Properties

Molecular Formula	C₃₁H₃₈F₂N₈O
Molecular Weight	576.7 g/mol
XLogP3	5.7
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	10
Rotatable Bond Count	8
Exact Mass	576.31366419 g/mol
Monoisotopic Mass	576.31366419 g/mol
Topological Polar Surface Area	84.2 Å²
Heavy Atom Count	42
Formal Charge	0
Complexity	855
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1